Flexion’s Slow-Release Steroid Now On Faster Track With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Following guidance from the agency on injectable osteoarthritis drug FX006, Flexion plans to file first with single-dose studies instead of waiting for longer-term data for repeated doses. This will speed up initial Phase III work by one year, the firm says.
You may also be interested in...
No Longer Aiming To Partner At Proof-of-Concept, Flexion Raises $20M For Late-Stage Trials
Now focused on two key programs in its osteoarthritis portfolio, the Massachusetts drug developer will align itself for a more traditional exit rather than a Big Pharma partnership.
Flexion Selects First Four Programs And Gets $9 Million From Pfizer Venture Fund
Modeled on Lilly's Chorus unit, Flexion purports to bring candidates to proof-of-concept quicker and cheaper than a Big Pharma typically can.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.